-

Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced an upcoming oral presentation related to MAR002, the company’s potential first-in-class, anti-growth hormone receptor (GHR) antibody being developed for acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO), being held from July 12-15, 2025 in San Francisco, CA.

Details of the oral presentation are as follows:

Title: Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly
Session Title: OR12 - NEUROENDOCRINOLOGY AND PITUITARY: Management of Pituitary Disorders
Session Date and Time: Sunday, July 13, 2025, 1:30 p.m. – 3:00 p.m. PT

About Marea Therapeutics

Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.

Contacts

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

Industry:

Marea Therapeutics, Inc.

Release Versions
English

Contacts

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

More News From Marea Therapeutics, Inc.

Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced positive topline results from its first-in-human Phase 1 study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR) for the treatment of acromegaly. The company also highlighted key pipeline...

Marea Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that Josh Lehrer, M.D., chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT. Dr. Lehrer will provide an overview of Marea’s pipeline, including MAR001 a fi...

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first participant has been enrolled in Marea’s Phase 1 study evaluating MAR002 for the treatment of acromegaly. Acromegaly is a chronic, rare, systemic disease most often caused by a growth hormone (GH)-secreting pituitary adenoma,...
Back to Newsroom